Hopp til innhold

Get alerts of updates about «Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review

Project

Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review - project description

Published Updated

The NIPH will evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer.


Summary

The Institute of Public Health has been commissioned to evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The Norwegian Medicines Agency (NoMA) will evaluate the treatment effect and safety of the drug Entrectinib (Rozlytrek) in the same population.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Gerd Monika Flodgren, Norwegian Institute of Public Health

Project participants

Vida Hamidi, Norwegian Institute of Public Health
Elisabet Vivianne Hafstad, Norwegian Institute of Public Health

Start

23.09.2020

End

15.02.2021

Status

Active

Project owner/ Project manager

Norwegian Institute of Public Health

Project description

ROS1 projectplan.pdf

Project manager

Gerd Monika Flodgren